Exicure reported a net loss of $9.7 million for fiscal year 2024, compared to a $16.9 million loss in 2023. Revenue was $0.5 million from a patent license agreement, while operating expenses decreased to $12.7 million from $15.0 million in 2023. The company recorded a $5.7 million right-of-use asset impairment loss related to its Chicago office lease.The company underwent significant strategic changes in 2024, including selling its historical biotechnology intellectual property and assets for $1.5 million. HiTron Systems acquired a controlling 53% stake through investments totaling $10 million, while SangSang Investment & Securities invested $2 million for a 6.9% stake. The company also completed a 1-for-5 reverse stock split in August 2024.As of December 31, 2024, Exicure had cash and cash equivalents of $12.5 million. The company continues to explore strategic alternatives and growth opportunities through potential transactions. In January 2025, Exicure acquired GPCR Therapeutics USA and entered into a license agreement to develop GPCR's technologies. Management noted substantial doubt about the company's ability to continue as a going concern without additional funding.

Exicure reported a net loss of $9.7 million for fiscal year 2024, compared to a $16.9 million loss in 2023. Revenue was $0.5 million from a patent license agreement, while operating expenses decreased to $12.7 million from $15.0 million in 2023. The company recorded a $5.7 million right-of-use asset impairment loss related to its Chicago office lease.The company underwent significant strategic changes in 2024, including selling its historical biotechnology intellectual property and assets for $1.5 million. HiTron Systems acquired a controlling 53% stake through investments totaling $10 million, while SangSang Investment & Securities invested $2 million for a 6.9% stake. The company also completed a 1-for-5 reverse stock split in August 2024.As of December 31, 2024, Exicure had cash and cash equivalents of $12.5 million. The company continues to explore strategic alternatives and growth opportunities through potential transactions. In January 2025, Exicure acquired GPCR Therapeutics USA and entered into a license agreement to develop GPCR's technologies. Management noted substantial doubt about the company's ability to continue as a going concern without additional funding.